Around 27% of essential drugs on the FDA list are categorised as 'at risk' due to uncertain supply chains. CyanoCapture is an advanced Synthetic Biology company that is leveraging the world's fastest carbon-negative cell to synthesise drug precursor molecules at lower cost and address this problem.